Skip to main content

Table 5 Summary of related meta-analysis for a first-line treatment of mCRC

From: Efficacy and safety of triplet chemotherapy plus anti-EGFR agents in metastatic colorectal cancer: a systematic review and meta-analysis

Meta-analysis

Included studies

Treatment

ORR

mPFS (month)

mOS (month)

SRR

Grade3/4 toxicity

Cremolini C [32]

CHARTA

OLIVIA STEAM TRIBE TRIBE2

bev+3-CT vs bev+2CTa

64.5 vs 53.6%

OR 1.57, P<0.001

12.2 vs 9,9

HR:0.74, P<0.001

28.9 vs 24.5

HR:0.81, P<0.001

16.4 vs 11.8%

OR 1.48, P=0.007

Neutropenia 45.8 vs 21.5%; P<0.001

FN 6.3 vs 3.7%; P=0.019

Diarrhea 17.8 vs 8.4%; P<0.001

C Bokemeyer [33]

CRYSTAL

OPUS

Cet+2CT

vs

2CT

60.7 vs 40.9%

OR 2.27, P <0.0001

10.9 vs 7.7

HR 0.64, P<0.0001

24.8 vs 21.1

HR 0.84, P =0.0048

NA

NA

F Pietrantonio [34]

Valentino

TRIBE

TRIBE2

STEAM

CHARTA.

pan+3CT vs bev+3CT

73 vs 77%

OR 0.79, P =0.4

11.4 vs 13.3

HR 0.83, P =0.11

30.3 vs 33.1

HR 0.8, P =0.14

22 vs 18%

P =0.51

Neutropenia 26 vs 48%; P =0.001

Diarrhea 14 vs 6%; P =0.82

Febrile stomatitis 8 vs 6%; P =0.67

G Tomasello [35]

11 studies

Bev+3CT

69%

(95%CI, 65–72%)

12.4

(95%CI,10-14.3)

30.2

(95%CI,26.5-33.7)

36.6%

(95%CI,24.6%-50.5%)

NA

  1. aAll KRAS and BRAF wild type; ORR Objective response rate, SRR Secondary resection rate, mPFS Median progression-free survival, mOS Median overall survival, 2CT Doublet chemotherapy, 3CT Triplet chemotherapy, FN Febrile neutropenia